Behзet’s syndrome - Pipeline Insight, 2021

September 2021 | 60 pages | ID: BB33402615C1EN
DelveInsight

Abstracts

This report can be delivered to the clients within 48 hours

DelveInsight’s, “Behзet’s syndrome - Pipeline Insight, 2021,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Behзet’s syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Behзet’s syndrome Understanding

Behзet’s syndrome: Overview

Behзet’s syndrome is a rare multisystem inflammatory disorder characterized by ulcers affecting the mouth and genitals, various skin lesions, and abnormalities affecting the eyes. Symptoms include mucous membrane lesions of the mouth (canker sores) and genitals (ulcers) that tend to disappear and recur spontaneously. Inflammation of the eyes (anterior uveitis, posterior uveitis, or panuveitis) also affects individuals with Behзet’s syndrome. Additional systems of the body may also be affected including the joints, blood vessels, central nervous system, and/or digestive tract. The exact cause of Behзet’s syndrome is unknown.

'Behзet’s syndrome - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Behзet’s syndrome pipeline landscape is provided which includes the disease overview and Behзet’s syndrome treatment guidelines. The assessment part of the report embraces, in depth Behзet’s syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Behзet’s syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Behзet’s syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Behзet’s syndrome.

Behзet’s syndrome Emerging Drugs Chapters

This segment of the Behзet’s syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Behзet’s syndrome Emerging Drugs

• Hemay005: Tianjin Hemay Pharmaceutical

Hemay005 is an orally available Type 4 cyclic nucleotide phosphodiesterase inhibitor. . The company is conducting Phase II study to evaluate the efficacy and safety of Hemay005 in the treatment of Behзet Disease.

• Canakinumab: Novartis

Canakinumab is a human monoclonal IgG1 that selectively neutralizes IL-1?, inhibiting its binding to IL-1RI and all cytokine-dependent signaling pathways. This results in the suppression of inflammation in patients with disorders of autoimmune origin.

Further product details are provided in the report.

Behзet’s syndrome: Therapeutic Assessment

This segment of the report provides insights about the different Behзet’s syndrome drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Behзet’s syndrome

There are approx. 3+ key companies which are developing the therapies for Behзet’s syndrome. The companies which have their Behзet’s syndrome drug candidates in the most advanced stage, i.e. phase II include, Tianjin Hemay Pharmaceutical.

• Phases

DelveInsight’s report covers around 3+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Behзet’s syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Behзet’s syndrome: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Behзet’s syndrome therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Behзet’s syndrome drugs.

Behзet’s syndrome Report Insights

• Behзet’s syndrome Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Behзet’s syndrome Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Behзet’s syndrome drugs?
• How many Behзet’s syndrome drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Behзet’s syndrome?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Behзet’s syndrome therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Behзet’s syndrome and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Tianjin Hemay Pharmaceutical
• Actelion Pharmaceuticals
• Novartis
• Silk Road Therapies, Inc.

Key Products

• Hemay005
• Bosentan
• Canakinumab

Contents

Introduction
Executive Summary
Behзet’s syndrome: Overview
  Causes
  Mechanism of Action
  Signs and Symptoms
  Diagnosis
  Disease Management
Pipeline Therapeutics
  Comparative Analysis
Therapeutic Assessment
  Assessment by Product Type
  Assessment by Stage and Product Type
  Assessment by Route of Administration
  Assessment by Stage and Route of Administration
  Assessment by Molecule Type
  Assessment by Stage and Molecule Type
Behзet’s syndrome – DelveInsight’s Analytical Perspectives
Mid Stage Products (Phase II)
  Comparative Analysis
Hemay005: Tianjin Hemay Pharmaceutical
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report.
Early Stage Products (Phase I)
  Comparative Analysis
Drug name: Company name
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report.
Inactive Products
  Comparative Analysis
Behзet’s syndrome Key Companies
Behзet’s syndrome Key Products
Behзet’s syndrome- Unmet Needs
Behзet’s syndrome- Market Drivers and Barriers
Behзet’s syndrome- Future Perspectives and Conclusion
Behзet’s syndrome Analyst Views
Behзet’s syndrome Key Companies
Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Behзet’s syndrome
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Behзet’s syndrome
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products